These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 39029989)
1. Cannabidiol as an antipsychotic drug. Fabris D; Lisboa JR; Guimarães FS; Gomes FV Int Rev Neurobiol; 2024; 177():295-317. PubMed ID: 39029989 [TBL] [Abstract][Full Text] [Related]
2. A systematic review of the antipsychotic properties of cannabidiol in humans. Iseger TA; Bossong MG Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194 [TBL] [Abstract][Full Text] [Related]
3. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464 [TBL] [Abstract][Full Text] [Related]
4. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Zuardi AW; Crippa JA; Hallak JE; Bhattacharyya S; Atakan Z; Martin-Santos R; McGuire PK; Guimarães FS Curr Pharm Des; 2012; 18(32):5131-40. PubMed ID: 22716160 [TBL] [Abstract][Full Text] [Related]
5. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. Roser P; Vollenweider FX; Kawohl W World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):208-19. PubMed ID: 20218784 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Mandolini GM; Lazzaretti M; Pigoni A; Oldani L; Delvecchio G; Brambilla P Epidemiol Psychiatr Sci; 2018 Aug; 27(4):327-335. PubMed ID: 29789034 [TBL] [Abstract][Full Text] [Related]
7. Investigating Cannabidiol's potential as a supplementary treatment for schizophrenia: A narrative review. Denis Völker JS; Micluția IV; Vinași RC Eur J Pharmacol; 2024 Sep; 979():176821. PubMed ID: 39068976 [TBL] [Abstract][Full Text] [Related]
8. Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors. Rodrigues da Silva N; Gomes FV; Sonego AB; Silva NRD; Guimarães FS Pharmacol Res; 2020 Jun; 156():104749. PubMed ID: 32151683 [TBL] [Abstract][Full Text] [Related]
9. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study. Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109 [TBL] [Abstract][Full Text] [Related]
10. Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum. Pedrazzi JFC; Sales AJ; Guimarães FS; Joca SRL; Crippa JAS; Del Bel E Prog Neuropsychopharmacol Biol Psychiatry; 2021 Dec; 111():110352. PubMed ID: 34015384 [TBL] [Abstract][Full Text] [Related]
11. Medical use of cannabis. Cannabidiol: a new light for schizophrenia? Deiana S Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356 [TBL] [Abstract][Full Text] [Related]
12. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914 [TBL] [Abstract][Full Text] [Related]
13. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis. Hahn B Schizophr Bull; 2018 Jan; 44(1):46-53. PubMed ID: 29083450 [TBL] [Abstract][Full Text] [Related]
15. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. García-Gutiérrez MS; Navarrete F; Gasparyan A; Austrich-Olivares A; Sala F; Manzanares J Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33228239 [TBL] [Abstract][Full Text] [Related]
16. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Campos AC; Moreira FA; Gomes FV; Del Bel EA; Guimarães FS Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3364-78. PubMed ID: 23108553 [TBL] [Abstract][Full Text] [Related]
17. Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice. Gomes FV; Issy AC; Ferreira FR; Viveros MP; Del Bel EA; Guimarães FS Int J Neuropsychopharmacol; 2014 Oct; 18(5):. PubMed ID: 25618402 [TBL] [Abstract][Full Text] [Related]
18. Cannabidiol, but Not Δ9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of Psychosis. Mielnik CA; Li CK; Ramsey AJ; Salahpour A; Burnham WM; Ross RA Cannabis Cannabinoid Res; 2024 Feb; 9(1):174-187. PubMed ID: 36251462 [No Abstract] [Full Text] [Related]
19. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol. Gomes FV; Llorente R; Del Bel EA; Viveros MP; López-Gallardo M; Guimarães FS Schizophr Res; 2015 May; 164(1-3):155-63. PubMed ID: 25680767 [TBL] [Abstract][Full Text] [Related]
20. Does cannabidiol have a role in the treatment of schizophrenia? Gururajan A; Malone DT Schizophr Res; 2016 Oct; 176(2-3):281-290. PubMed ID: 27374322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]